Loading organizations...
§ Private Profile · New York City, NY, USA
Biopharmaceutical company developing and commercializing biopharmaceuticals for Asian markets, focused on multiple therapeutic areas.
Everest Medicines is a Shanghai, China-based biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing pharmaceutical products and vaccines for unmet medical needs across Asian markets. The publicly listed enterprise operates with a workforce of 812 employees and maintains an estimated enterprise value of $1.34 billion. Its clinical pipeline combines in-house research with in-licensing innovative assets across therapeutic areas such as renal, autoimmune, oncology, cardiovascular, and infectious diseases. The firm utilizes a scalable commercialization platform, highlighted by its drug NEFECON generating over RMB 1 billion in sales during its first three quarters post-launch. The organization is backed by major shareholder CBC Group and led by key executives including Honorary Chairman Wei Fu, Chairman Yifang Wu, and Chief Executive Officer Rogers Yongqing Luo. Everest Medicines was founded in 2017 to target patient populations in Greater China.
Everest Medicines has raised $310.0M across 1 funding round.
Everest Medicines has raised $310.0M in total across 1 funding round.
Everest Medicines has raised $310.0M across 1 funding round. Most recently, it raised $310.0M Series C in June 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 5, 2020 | $310M Series C | Hillhouse Capital, John HO, Jiashan SDIC, RA Capital Management | WEI FU, Cormorant Asset Management, Decheng Capital, GT Fund, HBM Healthcare Investments, Janus Henderson Investors, Octagon Capital, Pavilion Capital, Rock Springs Capital | Announced |
Everest Medicines has raised $310.0M in total across 1 funding round.
Everest Medicines's investors include Hillhouse Capital, John Ho, Jiashan SDIC, RA Capital Management, Wei Fu, Cormorant Asset Management, Decheng Capital, GT Fund, HBM Healthcare Investments, Janus Henderson Investors, Octagon Capital, Pavilion Capital.